Where you areHR-positive / HER2-negative breast cancer

Back to the HR-positive / HER2-negative breast cancer hub →118 centres

Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.

Where you are

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

Site: Breast (all subtypes) (shared total; subtype split not reported). World: 2,296,840 new cases a year.

#	Country	New cases	Incidence ASR
1	China	357,161	33.0
2	United States of America	274,375	95.9
3	India	192,020	26.6
4	Brazil	94,728	63.1
5	Japan	91,916	74.4
6	Russian Federation	78,839	57.7
7	Germany	74,016	77.0
8	Indonesia	66,271	41.8
9	France (metropolitan)	65,659	105.4
10	United Kingdom	58,756	94.0

GLOBOCAN reports breast cancer as one site. HR+/HER2- disease is roughly 70% of cases; the figures shown are for all breast cancer.

Show deaths by countryGLOBOCAN's estimated deaths for the same countries, for readers who want them.

Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.

#	Country	New cases	Deaths
1	China	357,161	74,986
2	United States of America	274,375	42,900
3	India	192,020	98,337
4	Brazil	94,728	22,189
5	Japan	91,916	17,638
6	Russian Federation	78,839	22,115
7	Germany	74,016	20,601
8	Indonesia	66,271	22,598
9	France (metropolitan)	65,659	14,739
10	United Kingdom	58,756	12,122

World: 2,296,840 new cases and 666,103 deaths a year (GLOBOCAN 2022).

Expert centres

Where the expertise is

Expert centres

155 centres in 54 countries · 13 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

155 centres


Gustave Roussy Villejuif · cancer center Programme: Breast ADC trials	France	none recorded	0	1,862	31,707	ZAP-X gyroscopic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)	#6
The Royal Marsden London · cancer center Programme: Breast cancer	United Kingdom	none recorded	1	1,030	18,019	MR-guided adaptive radiotherapy PARP inhibitors	#7
National Cancer Center Hospital Tokyo · government	Japan	none recorded	0	1,599	21,937	none recorded	#13
Hospital General Universitario Gregorio Marañón Madrid · hospital Programme: Breast cancer (GEICAM)	Spain	none recorded	0	632	5,719	none recorded	#40
Cancer Hospital, Chinese Academy of Medical Sciences Beijing · cancer center	China	none recorded	1	365	3,800	none recorded	#50
The Institute of Cancer Research London · research institute	United Kingdom	none recorded	3	637	10,594	none recorded	-
NRG Oncology Philadelphia, PA · consortium	United States	none recorded	2	87	2,130	none recorded	-
Breast Cancer Trials Newcastle, NSW · consortium	Australia	none recorded	2	10	554	Endocrine therapy (SERMs, AIs, SERDs)PARP inhibitors	-
Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre London · hospital Programme: Breast cancer and PARP inhibitors	United Kingdom	none recorded	1	693	7,168	PARP inhibitors Multi-cancer early detection (MCED)Robotic & minimally invasive surgery IMRT / IGRT (modern external beam)	-
ETOP IBCSG Partners Foundation Bern · consortium	Switzerland	none recorded	1	82	2,450	Endocrine therapy (SERMs, AIs, SERDs)Immune checkpoint inhibitors	-
Montefiore Einstein Comprehensive Cancer Center Bronx, NY · cancer center Programme: Breast cancer (TAILORx)	United States	NCI comprehensive	1	49	182	Optical & fluorescence imaging	-
Breast International Group (BIG) Brussels · consortium	Belgium	none recorded	1	41	1,109	none recorded	-
Austrian Breast & Colorectal Cancer Study Group Vienna · consortium	Austria	none recorded	1	32	166	CDK4/6 inhibitors Endocrine therapy (SERMs, AIs, SERDs)	-
Canadian Cancer Trials Group (CCTG) Kingston, ON · consortium Programme: Breast endocrine therapy trials (MA series)	Canada	none recorded	1	32	323	Exercise & lifestyle oncology SBRT / SABR (stereotactic radiotherapy)	-
EORTC Brussels · consortium	Belgium	none recorded	1	not matched	-	none recorded	-

(showing the first 15)

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with HR-positive / HER2-negative breast cancer but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.

Model panel1 model

Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.

FableAnthropic · v5.12026-09-17low confidence

The record's epidemiology and its account of adjuvant CDK4/6 inhibitors are consistent with the listed sources, and the treatment sequence it describes (endocrine plus CDK4/6 first, genotype-directed second line, ADCs before chemotherapy) hangs together. Most of what makes the record distinctive, however, cannot be checked against its three sources: the September 2026 camizestrant approval and advisory vote, the 2026 vepdegestrant and gedatolisib approvals, the ESMO-MCBS grades (which are attributed to an NCCN document that would not contain them), and the claim that HR-positive disease accounts for most breast cancer deaths. Internal problems include heavy duplication (Beatson, tamoxifen, palbociclib, TAILORx, HER2-low and 2026 each appear twice in the history; subtypes, biomarkers and stateOfArt repeat items; two separate 'metastatic first line' settings exist), inavolisib placed in both first and second line, the same NCCN URL used for both screening and treatment settings, and an unexplained 'spike' tag. Stage-based prognosis is absent.

Right 2Missing 1Unclear 5Show verdicts

Right
HR-positive disease makes up about 70% of the 2.3 million breast cancers diagnosed each year, and there are 670,000 annual breast cancer deaths.
The incidence and mortality totals match the GLOBOCAN 2022 figures given in the Wikipedia article, which also describes roughly 70% of breast cancers as oestrogen receptor-positive.
Wikipedia
Unclear
Because it can recur late, it accounts for the majority of the 670,000 annual breast cancer deaths.
None of the listed sources breaks breast cancer mortality down by receptor subtype. The claim is plausible given the subtype's share of cases, but the record cites nothing that quantifies it.
Wikipedia
Unclear
Since September 2026 camizestrant is switched in at molecular progression on emergent ESR1 mutation (SERENA-6; accelerated approval 4 Sep 2026), which the FDA endorsed over a negative advisory vote.
The record itself marks NCCN inclusion as pending, and none of the three listed sources documents a September 2026 approval or an advisory committee vote. The same applies to the 2026 vepdegestrant and gedatolisib approvals and the persevERA result; these rest on linked records rather than on any cited source.
Guideline (Screening and diagnosis)
Unclear
ESMO-MCBS grades such as 'A (monarchE); A (NATALEE)' and '4-5 (MONALEESA-2, -3, -7); 2 (PALOMA-2); 2 (MONARCH 3)' are given under version 'NCCN Guidelines: Breast Cancer'.
ESMO-MCBS scores are published by ESMO, not by NCCN. The cited PMC article is an NCCN document and would not carry these grades, so the scores cannot be checked against the record's own sources and appear to be attributed to the wrong document.
NCCN Guidelines: Breast Cancer (Early stage)
Unclear
Screening and diagnosis: mammography ± tomosynthesis; supplemental MRI for dense breasts or high risk, cited to NCCN 'Breast Cancer Screening'.
The URL given is the same one used for the treatment settings (category=1&id=1419). NCCN publishes screening and diagnosis as a separate guideline, so the reference as written does not clearly point to the document the guideline field names.
Guideline (Screening and diagnosis)
Unclear
Metastatic second line: genotype-directed capivasertib, inavolisib, alpelisib, everolimus.
Inavolisib is listed here as a second-line agent, but a later entry in the same record places it in first line for PIK3CA-mutant relapse on or within 12 months of adjuvant endocrine therapy (INAVO120), consistent with the trial described in the linked record. The two settings contradict each other and the cited NCCN document would need to be checked to settle placement.
NCCN Guidelines: Breast Cancer (Early stage)
Right
NCCN Category 1, preferred: adjuvant abemaciclib (monarchE) and ribociclib (NATALEE) in high-risk disease.
The cited NCCN document is the appropriate source for adjuvant CDK4/6 inhibitor recommendations and both agents carry category 1 listings in high-risk early disease. The 'preferred' qualifier and the exact eligibility criteria should be read against the specific guideline version, which the record does not name.
NCCN Guidelines: Breast Cancer (Early stage)
Missing
Prognosis and survival by stage for HR-positive / HER2-negative disease.
The record gives a single metastatic median overall survival figure (MONALEESA-2, 63.9 months) and no survival estimates for early-stage or node-positive disease, despite describing the disease as 'slow-evolving' and late-recurring. The Wikipedia article provides stage-based survival that could anchor this, and a cancer record should state expected outcomes.
Wikipedia

Human reviews sit on top of the panel. Add a clinical review or see the review queue.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file · history

Wikipedia

Breast cancer

Sources & links

Wikipedia

Where you areHR-positive / HER2-negative breast cancer

Back to the HR-positive / HER2-negative breast cancer hub →118 centres

Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.

Where you are

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

Site: Breast (all subtypes) (shared total; subtype split not reported). World: 2,296,840 new cases a year.

#	Country	New cases	Incidence ASR
1	China	357,161	33.0
2	United States of America	274,375	95.9
3	India	192,020	26.6
4	Brazil	94,728	63.1
5	Japan	91,916	74.4
6	Russian Federation	78,839	57.7
7	Germany	74,016	77.0
8	Indonesia	66,271	41.8
9	France (metropolitan)	65,659	105.4
10	United Kingdom	58,756	94.0

GLOBOCAN reports breast cancer as one site. HR+/HER2- disease is roughly 70% of cases; the figures shown are for all breast cancer.

Show deaths by countryGLOBOCAN's estimated deaths for the same countries, for readers who want them.

#	Country	New cases	Deaths
1	China	357,161	74,986
2	United States of America	274,375	42,900
3	India	192,020	98,337
4	Brazil	94,728	22,189
5	Japan	91,916	17,638
6	Russian Federation	78,839	22,115
7	Germany	74,016	20,601
8	Indonesia	66,271	22,598
9	France (metropolitan)	65,659	14,739
10	United Kingdom	58,756	12,122

World: 2,296,840 new cases and 666,103 deaths a year (GLOBOCAN 2022).

Expert centres

Where the expertise is

Expert centres

155 centres in 54 countries · 13 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

155 centres


Gustave Roussy Villejuif · cancer center Programme: Breast ADC trials	France	none recorded	0	1,862	31,707	ZAP-X gyroscopic radiosurgery Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)	#6
The Royal Marsden London · cancer center Programme: Breast cancer	United Kingdom	none recorded	1	1,030	18,019	MR-guided adaptive radiotherapy PARP inhibitors	#7
National Cancer Center Hospital Tokyo · government	Japan	none recorded	0	1,599	21,937	none recorded	#13
Hospital General Universitario Gregorio Marañón Madrid · hospital Programme: Breast cancer (GEICAM)	Spain	none recorded	0	632	5,719	none recorded	#40
Cancer Hospital, Chinese Academy of Medical Sciences Beijing · cancer center	China	none recorded	1	365	3,800	none recorded	#50
The Institute of Cancer Research London · research institute	United Kingdom	none recorded	3	637	10,594	none recorded	-
NRG Oncology Philadelphia, PA · consortium	United States	none recorded	2	87	2,130	none recorded	-
Breast Cancer Trials Newcastle, NSW · consortium	Australia	none recorded	2	10	554	Endocrine therapy (SERMs, AIs, SERDs)PARP inhibitors	-
Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre London · hospital Programme: Breast cancer and PARP inhibitors	United Kingdom	none recorded	1	693	7,168	PARP inhibitors Multi-cancer early detection (MCED)Robotic & minimally invasive surgery IMRT / IGRT (modern external beam)	-
ETOP IBCSG Partners Foundation Bern · consortium	Switzerland	none recorded	1	82	2,450	Endocrine therapy (SERMs, AIs, SERDs)Immune checkpoint inhibitors	-
Montefiore Einstein Comprehensive Cancer Center Bronx, NY · cancer center Programme: Breast cancer (TAILORx)	United States	NCI comprehensive	1	49	182	Optical & fluorescence imaging	-
Breast International Group (BIG) Brussels · consortium	Belgium	none recorded	1	41	1,109	none recorded	-
Austrian Breast & Colorectal Cancer Study Group Vienna · consortium	Austria	none recorded	1	32	166	CDK4/6 inhibitors Endocrine therapy (SERMs, AIs, SERDs)	-
Canadian Cancer Trials Group (CCTG) Kingston, ON · consortium Programme: Breast endocrine therapy trials (MA series)	Canada	none recorded	1	32	323	Exercise & lifestyle oncology SBRT / SABR (stereotactic radiotherapy)	-
EORTC Brussels · consortium	Belgium	none recorded	1	not matched	-	none recorded	-

(showing the first 15)

Model panel1 model

Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.

FableAnthropic · v5.12026-09-17low confidence

Right 2Missing 1Unclear 5Show verdicts

Right
HR-positive disease makes up about 70% of the 2.3 million breast cancers diagnosed each year, and there are 670,000 annual breast cancer deaths.
The incidence and mortality totals match the GLOBOCAN 2022 figures given in the Wikipedia article, which also describes roughly 70% of breast cancers as oestrogen receptor-positive.
Wikipedia
Unclear
Because it can recur late, it accounts for the majority of the 670,000 annual breast cancer deaths.
None of the listed sources breaks breast cancer mortality down by receptor subtype. The claim is plausible given the subtype's share of cases, but the record cites nothing that quantifies it.
Wikipedia
Unclear
Since September 2026 camizestrant is switched in at molecular progression on emergent ESR1 mutation (SERENA-6; accelerated approval 4 Sep 2026), which the FDA endorsed over a negative advisory vote.
The record itself marks NCCN inclusion as pending, and none of the three listed sources documents a September 2026 approval or an advisory committee vote. The same applies to the 2026 vepdegestrant and gedatolisib approvals and the persevERA result; these rest on linked records rather than on any cited source.
Guideline (Screening and diagnosis)
Unclear
ESMO-MCBS grades such as 'A (monarchE); A (NATALEE)' and '4-5 (MONALEESA-2, -3, -7); 2 (PALOMA-2); 2 (MONARCH 3)' are given under version 'NCCN Guidelines: Breast Cancer'.
ESMO-MCBS scores are published by ESMO, not by NCCN. The cited PMC article is an NCCN document and would not carry these grades, so the scores cannot be checked against the record's own sources and appear to be attributed to the wrong document.
NCCN Guidelines: Breast Cancer (Early stage)
Unclear
Screening and diagnosis: mammography ± tomosynthesis; supplemental MRI for dense breasts or high risk, cited to NCCN 'Breast Cancer Screening'.
The URL given is the same one used for the treatment settings (category=1&id=1419). NCCN publishes screening and diagnosis as a separate guideline, so the reference as written does not clearly point to the document the guideline field names.
Guideline (Screening and diagnosis)
Unclear
Metastatic second line: genotype-directed capivasertib, inavolisib, alpelisib, everolimus.
Inavolisib is listed here as a second-line agent, but a later entry in the same record places it in first line for PIK3CA-mutant relapse on or within 12 months of adjuvant endocrine therapy (INAVO120), consistent with the trial described in the linked record. The two settings contradict each other and the cited NCCN document would need to be checked to settle placement.
NCCN Guidelines: Breast Cancer (Early stage)
Right
NCCN Category 1, preferred: adjuvant abemaciclib (monarchE) and ribociclib (NATALEE) in high-risk disease.
The cited NCCN document is the appropriate source for adjuvant CDK4/6 inhibitor recommendations and both agents carry category 1 listings in high-risk early disease. The 'preferred' qualifier and the exact eligibility criteria should be read against the specific guideline version, which the record does not name.
NCCN Guidelines: Breast Cancer (Early stage)
Missing
Prognosis and survival by stage for HR-positive / HER2-negative disease.
The record gives a single metastatic median overall survival figure (MONALEESA-2, 63.9 months) and no survival estimates for early-stage or node-positive disease, despite describing the disease as 'slow-evolving' and late-recurring. The Wikipedia article provides stage-based survival that could anchor this, and a cancer record should state expected outcomes.
Wikipedia

Human reviews sit on top of the panel. Add a clinical review or see the review queue.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file · history

Wikipedia

Breast cancer

Sources & links

Wikipedia